Sphera Funds Management LTD. Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Sphera Funds Management LTD. bought a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 68,333 shares of the company’s stock, valued at approximately $3,659,000. Sphera Funds Management LTD. owned about 0.13% of Janux Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Ratan Capital Management LP increased its stake in Janux Therapeutics by 522.6% during the fourth quarter. Ratan Capital Management LP now owns 179,307 shares of the company’s stock worth $9,600,000 after acquiring an additional 150,507 shares during the last quarter. Point72 Asset Management L.P. increased its stake in Janux Therapeutics by 57.0% during the fourth quarter. Point72 Asset Management L.P. now owns 621,383 shares of the company’s stock worth $33,269,000 after acquiring an additional 225,508 shares during the last quarter. ProShare Advisors LLC increased its stake in Janux Therapeutics by 23.9% during the fourth quarter. ProShare Advisors LLC now owns 10,384 shares of the company’s stock worth $556,000 after acquiring an additional 2,003 shares during the last quarter. Prosight Management LP increased its stake in Janux Therapeutics by 60.9% during the fourth quarter. Prosight Management LP now owns 329,768 shares of the company’s stock worth $17,656,000 after acquiring an additional 124,768 shares during the last quarter. Finally, MPM Bioimpact LLC increased its stake in Janux Therapeutics by 34.4% during the fourth quarter. MPM Bioimpact LLC now owns 230,000 shares of the company’s stock worth $12,314,000 after acquiring an additional 58,895 shares during the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Insider Activity at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 3,334 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $32.15, for a total value of $107,188.10. Following the sale, the insider now directly owns 82,139 shares in the company, valued at $2,640,768.85. This trade represents a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ra Capital Management, L.P. purchased 110,206 shares of the business’s stock in a transaction on Friday, March 7th. The stock was acquired at an average price of $31.02 per share, for a total transaction of $3,418,590.12. Following the completion of the purchase, the director now owns 10,141,287 shares of the company’s stock, valued at $314,582,722.74. This represents a 1.10% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders sold 10,001 shares of company stock worth $313,964. Company insiders own 8.10% of the company’s stock.

Janux Therapeutics Trading Up 2.9%

NASDAQ:JANX opened at $23.27 on Friday. The firm has a market cap of $1.38 billion, a PE ratio of -19.89 and a beta of 3.24. The stock has a fifty day moving average price of $28.76 and a 200 day moving average price of $40.94. Janux Therapeutics, Inc. has a 12-month low of $22.48 and a 12-month high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Equities analysts forecast that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Analyst Ratings Changes

Several research firms have issued reports on JANX. Scotiabank cut their target price on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a research note on Friday, February 28th. Wedbush restated an “outperform” rating and set a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Finally, HC Wainwright restated a “buy” rating and set a $70.00 price target on shares of Janux Therapeutics in a research report on Monday, March 3rd. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $95.25.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.